Bayer HealthCare has partnered with Comecer SPA, a provider of protection technologies in nuclear medicine, to expand its global distribution network for the Medrad Intego PET infusion system.
Through this agreement, Bayer and Comecer will provide customers with an integrated nuclear medicine solution that combines the clinical administration capabilities of Intego with the Comecer’s protection technologies for PET/CT centers around the world.
“This arrangement creates an end-to-end solution for customers, from isotope production to radiopharmaceutical infusion,” said Doug Descalzi, senior director of molecular imaging devices, Bayer HealthCare. “We’re pleased to be working with Comecer to not only provide greater patient access to Intego but also to provide comprehensive product solutions to nuclear medicine suites around the world.”
Intego—an FDA-cleared system for the administration of 18F-FDG and 18F-NaF—infuses doses on demand, providing clinicians with greater flexibility, added protection, and more accurate, repeatable, patient-specific dosing. With distribution through Comecer, clinicians in Europe and other markets will have easier access to this radiation dose reducing technology.
